RTP Mobile Logo

Saturday, June 2, 2018, Chicago, IL, 7:00 PM – 9:30 PM

An Evening with the Investigators: Perspectives on Key Questions and Emerging Research in the Management of Gastrointestinal Cancers

Event Details

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:30 PM – 7:00 PM (Central Time) — Registration and Dinner Buffet
7:00 PM – 9:30 PM (Central Time) — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Charles S Fuchs, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital
New Haven, Connecticut

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Scottsdale, Arizona

Yelena Y Janjigian, MD
Assistant Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Robin K Kelley, MD
Associate Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Andrew Ko, MD
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Scott Kopetz, MD, PhD
Associate Professor, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Andrew X Zhu, MD, PhD
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.


Meeting Format and Agenda

This unique activity will feature 4 separate content modules during which a pair of noted investigators will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Gastric Cancer — Dr Fuchs and Dr Janjigian

  • Choice of neoadjuvant therapy; published data with the FLOT regimen of docetaxel, oxaliplatin and fluorouracil/leucovorin
  • Practical integration of ramucirumab into current treatment algorithms for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma; clinical and research implications of the RAINFALL trial results
  • FDA approval of pembrolizumab for PD-L1-positive recurrent or advanced gastric/GEJ adenocarcinoma and current role in practice
  • Available data with and ongoing trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic or immunotherapeutic approaches
  • Other novel agents and strategies under investigation for metastatic gastric or GEJ adenocarcinoma (eg, regorafenib, TAS-102, andecaliximab)

MODULE 2: Pancreatic Adenocarcinoma (PAD) — Dr Ko and Dr Philip

  • Available data with, ongoing evaluation of and current clinical indications, if any, for the use of nanoparticle albumin-bound (nab) paclitaxel/gemcitabine or FOLFIRINOX as neoadjuvant or adjuvant therapy
  • Clinical and patient-specific factors influencing the selection of first- and second-line treatment of metastatic disease
  • Practical integration of nanoliposomal irinotecan into the current treatment algorithm
  • Biologic rationale for targeting cancer stemness pathways; mechanism of action, early clinical data and ongoing investigation with napabucasin
  • Other promising agents and strategies undergoing evaluation for the treatment of PAD

MODULE 3: Hepatocellular Carcinoma (HCC) — Dr Kelley and Dr Zhu

  • Available clinical trial data comparing lenvatinib to sorafenib for patients with advanced, unresectable HCC
  • Implications for clinical practice of the approval of regorafenib for patients with HCC previously treated with sorafenib; factors influencing patient selection for this therapeutic approach
  • Integration of nivolumab into the care of patients with advanced HCC; ongoing clinical trials of anti-PD-1/PD-L1 therapy in this patient population
  • Design, eligibility criteria and major efficacy and tolerability findings from the Phase III CELESTIAL trial comparing cabozantinib to placebo for patients with HCC who received prior sorafenib
  • Emerging Phase III data with ramucirumab as second-line therapy for patients with advanced HCC and elevated baseline alpha-fetoprotein

MODULE 4: Colorectal Cancer (CRC) — Dr Grothey and Dr Kopetz

  • Effect of primary tumor sidedness on prognosis and therapeutic decision-making for patients with metastatic CRC (mCRC)
  • Initial dosing and dose-escalation strategies with regorafenib; implications of the ReDOS study results
  • Integration of TAS-102 and regorafenib in the management of mCRC
  • Practical implementation of microsatellite instability (MSI)/mismatch repair (MMR) testing in patients with mCRC; role of anti-PD-1 antibodies in the management of MSI-high and MMR-deficient CRC
  • Biologic rationale for, available research evidence with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy, targeted therapy and other immunotherapies for patients with MSI-high/MMR-deficient and microsatellite-stable mCRC

CE Information

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal (GI) cancers.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Review recent data on therapeutic advances and changing practice standards in colorectal and noncolorectal GI cancers, and integrate this information, as appropriate, into current clinical care.
  • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer, considering biomarker profile, tumor location, prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
  • Consider age, PS and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
  • Communicate the benefits and risks of available and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular carcinoma.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in GI cancers, and counsel appropriately selected patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.


Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.



Thank you for your interest in our educational program.  At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM (Central Time) on Saturday, June 2nd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.